Hitchens
Member
- Joined
- Jan 27, 2019
- Messages
- 61
"In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (“Regeneron”) entered into a collaborative agreement to develop and commercialize Regeneron’s pain medication product, fasinumab. Results for two phase 3 clinical trials, FACT OA1 and FACT OA2, were released on August 5, 2020, indicating that the co-primary endpoints for fasinumab were achieved. Fasinumab 1 mg monthly demonstrated significant improvements in pain and physical function over placebo at week 16 and week 24, respectively. Fasinumab 1 mg monthly also showed nominally significant benefits in physical function in two trials and pain in one trial, when compared to the maximum FDA-approved prescription doses of non-steroidal anti-inflammatory drugs for osteoarthritis. ..."
Fasinumab is an anti-nerve growth factor medication, Eli Lilly and Pfizer's competitor sister med Tanezumab reported increased rates of osteoarthritis and skeletal side effects in trials back in 2019 at higher doses than Teva's Fasinumab. This class of non-opiate pain relief is very important research project in the opiod epidemic we live in, EVEN if it fails. Im curious about 'anti-nerve growth factor' side effects at the brain level.
Fasinumab is an anti-nerve growth factor medication, Eli Lilly and Pfizer's competitor sister med Tanezumab reported increased rates of osteoarthritis and skeletal side effects in trials back in 2019 at higher doses than Teva's Fasinumab. This class of non-opiate pain relief is very important research project in the opiod epidemic we live in, EVEN if it fails. Im curious about 'anti-nerve growth factor' side effects at the brain level.
